There is a long pathway between demonstrating efficacy in clinical trials of new anti-HIV technologies and proving effectiveness in “real world” settings. That pathway is paved with combinations of technological, behavioral, social, political, and economic factors that ultimately play out in the actions of individuals to take up (or resist taking up) HIV prevention and treatment methods and incorporate them into their daily lives. To a great extent, whether and how this occurs is a reflection of public engagement in HIV/AIDS science—from basic perceptions and attitudes about biomedical research; meanings people give to products, technologies, their bodies, and their relationships; participation in and knowledge of the outcomes of research; and communication about scientific processes and outcomes.
This session will examine how public engagement in science has evolved in the realm of HIV, including issues of inclusion, exclusion, exploitation and benefit, and what constitutes sound scientific research and actionable evidence.
Co-chairs: Judith Auerbach, Veronica Noseda
Speakers: Patricia Kingori, Pedro Goicochea, Kathleen MacQueen, Kane Race